Results 41 to 50 of about 23,043 (148)

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders. [PDF]

Front Oncol, 2022
Symeonidis A, Chondropoulos S, Verigou E, Lazaris V, Kourakli A, Tsirigotis P.   +5 more
europepmc   +1 more source

On‐Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients

Magnetic Resonance in Medicine, Volume 95, Issue 6, Page 3386-3395, June 2026.
ABSTRACT Purpose To improve accuracy of apparent diffusion coefficient (ADC) measurement across different bone‐marrow (BM) sites for myelofibrosis (MF) patients. Methods Vendor‐provided ADC gradient nonlinearity correction (GNC) was implemented for 41 MF study subjects on a 3T clinical scanner.
Dariya Malyarenko, Brian D. Ross, Johannes M. Peeters, Ajit Devaraj, Ramin Jafari, Humera Tariq, Kristen M. Pettit, Moshe Talpaz, Gary D. Luker, Thomas L. Chenevert   +9 more
wiley   +1 more source

Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina. [PDF]

Cancers (Basel), 2022
Pennella CL, Cassina TM, Rossi JG, Baialardo EM, Rubio P, Deu MA, Peruzzo L, Guitter MR, Sanchez de La Rosa CG, Alfaro EM, Felice MS.   +10 more
europepmc   +1 more source

Pre‐RAI Monocyte‐to‐Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate‐Risk DTC, While PNI and NRI Show No Prognostic Value

Clinical Endocrinology, Volume 104, Issue 6, Page 670-681, June 2026.
ABSTRACT Objective Differentiated thyroid carcinoma (DTC) has an excellent prognosis, but recurrence remains a clinical concern, especially in intermediate‐risk patients. Current stratification systems focus primarily on tumor characteristics, overlooking the host's biological capacity to counteract tumor progression.
Tommaso Piticchio, Francesco Galeano, Salvatore Volpe, Antonio Prinzi, Ignazio Barca, Andrea Scuto, Rosario Le Moli, Giulio Geraci, Andrea Tumminia, Sium Wolde Sellasie, Francesco Pallotti, Francesco Frasca   +11 more
wiley   +1 more source

Histamine and Serotonin Levels in Bone Marrow Stem Cells Niche as Potential Biomarkers of Systemic Mastocytosis and Myeloproliferative Disorders. [PDF]

Stem Cell Rev Rep, 2023
Janus T, Korbal U, Żukowski M, Lewosiuk A, Koper K, Żukowska A, Brzeźniakiewicz-Janus K.   +6 more
europepmc   +1 more source

What Is Your Diagnosis? Multiple Subcutaneous Lumps in a Horse

Veterinary Clinical Pathology, EarlyView.
Federica Meistro, Maria Virginia Ralletti, Riccardo Rinnovati, Alessandro Spadari, Maria Morini   +4 more
wiley   +1 more source

Diagnosing Systemic Mastocytosis: State of the Art

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 551-560, June 2026.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. [PDF]

J Clin Med, 2021
Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM.   +7 more
europepmc   +1 more source

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Cancer, Volume 132, Issue 10, 15 May 2026.
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek, Courtney D. DiNardo, Sanam Loghavi, Farhad Ravandi, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Elias Jabbour, Andrew Dunbar, Guilin Tang, Nicholas J. Short, Fadi G. Haddad, Hussein A. Abbas, Eitan Kugler, Abhishek Maiti, Ghayas C. Issa, Koichi Takahashi, Kapil Bhalla, Naveen Pemmaraju, Yesid Alvarado, Elizabeth J. Shpall, Uday Popat, Jeremy Ramdial, Richard E. Champlin, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jayastu Senapati   +26 more
wiley   +1 more source